Date: 2013-09-25
Type of information: Grant
Company: Consortium 3D-NET ( KalVista Pharmaceuticals (UK) University College Dublin (Ireland), Universidad de Valladolid (Spain), RenaSci Ltd (UK) and Gadea Grupo Farmacéutico (Spain))
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: €1.66 million
Funding type: grant
Planned used: The four-year project seeks to enable the development of new drugs for the treatment of ocular disease associated with inflammation, neovascularisation, edema and degeneration, through the complementary capabilities of the partners.
Others: * On September 25, 2013, KalVista Pharmaceuticals, an UK ophthalmology company with a focus on diabetic macular edema (DME), has announced that it is joining a group of academic and industry researchers to undertake the ‘3D-NET’ (‘Drug Discovery and Development of Novel Eye Therapeutics’) project. The four-year project seeks to enable the development of new drugs for the treatment of ocular disease associated with inflammation, neovascularisation, edema and degeneration, through the complementary capabilities of the partners. The project will be funded through a €1.66 million Marie Curie Industry-Academia Pathways and Partnerships (IAPP) grant award from the EU Seventh Framework Programme (612218/3D-NET).
KalVista brings expertise in ocular diseases resulting from diabetes, such as diabetic macular edema, an extensive library of novel compounds already screened for activity in the eye, and proven capabilities in the development of drugs from target identification through to in vitro pharmacology and safety.
Therapeutic area: Ophtalmological diseases
